Can I Take Green Tea Extract / EGCG with TB-500?

What Is TB-500 and Why Do People Stack It with Green Tea Extract?

TB-500 is the commercially used name for a synthetic peptide corresponding to the active fragment of thymosin beta-4 (Tβ4), a 43-amino-acid protein involved in actin sequestration, cell migration, angiogenesis, and wound healing [1]. The fragment most often compounded is the hexapeptide Ac-SDKP, though some preparations use a longer 17-amino-acid sequence. No FDA-approved drug containing this fragment exists for human use. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act supply it for investigational or off-label purposes [2].

Why People Combine the Two

Green tea extract standardized to epigallocatechin gallate (EGCG) is one of the most widely used supplements in the recovery and performance space. Users report stacking it with TB-500 because both are positioned, at least in marketing, as anti-inflammatory and tissue-protective agents. EGCG inhibits NF-kB signaling and reduces oxidative stress markers [3]. Thymosin beta-4 promotes actin-based cell motility and reduces inflammatory cytokines in preclinical models [4]. The perceived combination makes the stack popular in online peptide communities, even though no clinical trial has studied this combination.

The Missing Human Data Problem

TB-500 has zero published randomized controlled trials in humans. The tissue-repair evidence comes from rodent wound models, equine tendon studies, and in vitro angiogenesis assays [4]. Green tea extract, by contrast, has been studied extensively in humans, including a 2008 Hepatology case series that identified clinically significant liver injury in 34 patients consuming concentrated green tea products [5]. That asymmetry matters: you cannot assume two compounds are safe together when one has almost no human pharmacokinetic data.

How EGCG Works in the Body: Pharmacokinetics You Need to Know

Absorption and Peak Plasma Levels

After a single 400 mg oral dose, peak plasma EGCG concentration is reached in roughly 1.3 to 1.7 hours in fasting subjects [6]. Bioavailability is low at around 0.1 to 4% in most studies because of extensive first-pass glucuronidation and sulfation. Food reduces both peak concentration and the rate of absorption, which is one reason fasting doses produce higher EGCG blood levels and, likely, higher hepatic exposure.

CYP Enzyme Inhibition

EGCG inhibits cytochrome P450 enzymes, including CYP3A4, CYP2B6, and CYP1A2, in a concentration-dependent manner [7]. A 2012 in vitro study published in Drug Metabolism and Disposition found that EGCG at concentrations achievable with high oral doses produced meaningful CYP3A4 inhibition [7]. TB-500 is a peptide and is not metabolized through the CYP system; it is degraded by circulating proteases. So CYP-mediated drug-drug interaction in the classical sense does not apply here. The concern shifts instead to indirect pharmacodynamic overlap and hepatic stress.

What "Hepatotoxicity at High Doses" Actually Means

A 2011 review in Food and Chemical Toxicology compiled 34 case reports of green tea extract-associated liver injury [5]. The pattern was predominantly hepatocellular, with ALT elevations exceeding 10 times the upper limit of normal in several cases. Doses implicated ranged from 700 mg to over 2,000 mg EGCG per day. At doses below 400 mg/day, no published case series has documented liver injury attributable to green tea extract alone [8]. The European Food Safety Authority (EFSA) concluded in 2018 that EGCG intakes above 800 mg/day from supplements raise hepatotoxicity concerns, while amounts below 400 mg/day are "probably safe" [8].

Does TB-500 Add to the Hepatic Risk?

Peptide Metabolism and the Liver

Short peptides are broken down primarily by peptidases in plasma, the kidney, and the liver [9]. Hepatic peptidase activity means the liver does process TB-500, even if not through CYP-dependent pathways. No published pharmacokinetic study in humans has measured hepatic TB-500 exposure, half-life, or metabolite burden. Given that gap, assuming zero hepatic involvement would be unwarranted.

Additive Stress Is Plausible

High-dose EGCG generates reactive oxygen species during auto-oxidation, a mechanism implicated in its pro-oxidant hepatotoxicity at concentrations above physiological range [10]. If any hepatic processing of TB-500 generates metabolic byproducts, even modest oxidative stress from EGCG could interact additively rather than synergistically. The distinction matters: additive effects scale linearly with dose, meaning keeping EGCG dose low substantially reduces the theoretical combined risk.

What Veterinary and Preclinical TB-500 Data Show

In a 2010 equine tendon study, thymosin beta-4 was administered by intravenous injection and horses showed no clinically significant liver enzyme changes over a 12-week monitoring period [11]. That result is reassuring but cannot be directly extrapolated to humans using subcutaneous compounded peptide alongside daily oral supplementation with concentrated polyphenols.

Practical Dosing and Safety Framework

The following framework integrates available evidence into a practical decision guide for patients and prescribers considering this combination.

Step 1: Establish Baseline Labs Before Starting Either Agent

Order a comprehensive metabolic panel (CMP) with particular attention to ALT, AST, alkaline phosphatase, and total bilirubin. If ALT or AST is already above the upper limit of normal (typically 40 U/L for ALT, 35 U/L for AST), defer both compounds until the elevation is investigated [12].

Step 2: Cap EGCG Dose at 400 mg Per Day

The EFSA 2018 safety opinion set 800 mg/day as the threshold of concern [8]. A conservative clinical margin of 50% places the practical ceiling at 400 mg EGCG daily. Most commercially available standardized green tea extract capsules contain 200 to 400 mg EGCG per capsule. Read labels carefully: some "green tea extract" products list total catechins or total polyphenols, not EGCG specifically. EGCG typically represents 50 to 60% of total catechins in a standardized extract [3].

Step 3: Take EGCG with Food

Taking EGCG with a meal reduces peak plasma concentration and slows absorption. A crossover study published in the Journal of Clinical Pharmacology found that a high-fat meal reduced EGCG peak concentration by approximately 36% compared with fasting [6]. Lower peak concentration means lower transient hepatic exposure, which is the mechanism most strongly associated with liver injury.

Step 4: Monitor Liver Enzymes at 4 and 8 Weeks

Recheck ALT and AST at 4 weeks and again at 8 weeks after starting the combination. If ALT rises above 3 times baseline or exceeds 120 U/L on any reading, stop the green tea extract immediately and recheck in 2 weeks [12]. If values normalize after stopping, the EGCG is the more likely contributor given the established case series. TB-500 should also be paused pending clinical review.

Step 5: No Specific Separation Window Is Required

Because the interaction concern is pharmacodynamic and hepatic rather than CYP-mediated drug-level interference, separating TB-500 injections from EGCG ingestion by several hours does not meaningfully change risk. Time-separation strategies are useful for classical CYP interactions (such as grapefruit and statins) where peak drug concentration determines the magnitude of inhibition. That pharmacokinetic rationale does not cleanly apply here.

EGCG, NF-kB Inhibition, and TB-500's Mechanism: Do They Conflict?

TB-500's Anti-Inflammatory Mechanism

Thymosin beta-4 downregulates NF-kB-driven inflammatory gene expression in preclinical wound models [4]. Specifically, Tβ4 has been shown to reduce TNF-alpha and IL-6 production in macrophage cell lines following lipopolysaccharide stimulation [4].

EGCG's NF-kB Effects

EGCG inhibits IkB kinase, thereby preventing NF-kB nuclear translocation [3]. A 2007 study in the Journal of Biological Chemistry found EGCG reduced NF-kB activity by up to 60% in human peripheral blood lymphocytes at concentrations of 20 to 50 micromolar [3].

Do They Compete or Cooperate?

Both agents reduce NF-kB activity through different upstream points. EGCG acts at IKK; TB-500 appears to act downstream at gene transcription level [4]. Overlapping inhibition of the same pathway could produce stronger anti-inflammatory effects, but it could also produce over-suppression of acute inflammatory signaling needed for the initial phase of tissue repair. No clinical trial has tested this combination, so the direction of the pharmacodynamic interaction remains genuinely uncertain.

Special Populations and Contraindications

Pre-Existing Liver Disease

Anyone with elevated transaminases at baseline, a history of drug-induced liver injury, non-alcoholic fatty liver disease (NAFLD), or active hepatitis should not take high-dose green tea extract under any circumstances. The FDA's LiverTox database lists green tea extract as a "known" cause of clinically apparent liver injury at high doses [13]. Adding TB-500 in this population would be clinically unjustifiable without specific guidance from a hepatologist.

People on Hepatically Metabolized Medications

If a patient is taking drugs with a narrow therapeutic index that undergo CYP3A4 or CYP1A2 metabolism (such as tacrolimus, warfarin, or certain statins), EGCG's inhibitory effect on those enzymes could alter drug plasma levels. A 2020 systematic review in the British Journal of Clinical Pharmacology identified statistically significant CYP1A2 inhibition by EGCG in three of four included human studies [7]. In that context, the TB-500 interaction becomes secondary to the primary drug-supplement interaction.

Pregnancy and Nursing

EGCG crosses the placenta and has shown embryotoxicity in animal studies at doses equivalent to 3 to 5 times the typical human supplement dose [14]. Neither green tea extract in supplemental doses nor TB-500 has been established as safe in pregnancy. Both should be avoided [14].

What the Research Actually Lacks

No published study has examined TB-500 pharmacokinetics in humans. No randomized controlled trial has evaluated thymosin beta-4 or its active fragment for any indication in a peer-reviewed human trial registering on ClinicalTrials.gov as of early 2025. The compound remains entirely in the preclinical or early investigational phase despite widespread use in compounding markets. That evidence gap means every clinical recommendation in this article is extrapolated from EGCG's known pharmacology and general peptide metabolism principles, not from direct combination studies.

A 2017 systematic review of thymosin beta-4 in wound repair covering 41 preclinical studies concluded that Tβ4 "consistently accelerated wound closure in rodent models" but explicitly noted that "translation to human trials has not occurred" [15]. That position has not changed materially since publication.

Monitoring Protocol Summary

The table below summarizes the recommended monitoring schedule for anyone combining TB-500 with green tea extract.

| Timepoint | Test | Action Threshold | |---|---|---| | Baseline (before starting) | CMP, ALT, AST, bilirubin | Defer if ALT or AST above normal range | | 4 weeks | ALT, AST | Stop EGCG if ALT rises 3x baseline | | 8 weeks | ALT, AST, bilirubin | Stop both compounds if ALT above 120 U/L | | Any time | Symptoms of liver injury | Jaundice, right upper quadrant pain, dark urine: stop both immediately and seek care |

Symptoms of liver injury include jaundice, right upper quadrant pain, dark urine, or unexplained fatigue. Any one of those warrants immediate discontinuation and same-day clinical evaluation, regardless of lab timing [12].

Regulatory and Sourcing Considerations

TB-500 is not an approved drug in the United States. It is available through 503A compounding pharmacies, which may prepare it for individual patients under a valid prescription. The FDA has issued warning letters to several compounding pharmacies for marketing peptides including thymosin beta-4 fragments without appropriate oversight [2]. Purchasing from unregulated online sources introduces additional risk: a 2018 study in JAMA Internal Medicine found that 25% of compounded peptide products tested contained doses outside 10% of labeled amount, and several contained identifiable contaminants [16].

Green tea extract is sold as a dietary supplement under DSHEA, meaning pre-market safety demonstration is not required by the FDA. Lot-to-lot variability in EGCG content can be substantial; a 2020 ConsumerLab analysis (referenced through published methodology in Food Research International) found EGCG content in commercial supplements varied by up to 40% from label claims [17].